PLX Share Price Performance
US$2.50
1.48 (145.10%)
82.1% undervalued intrinsic discount
US$14.00
Fair Value
Price US$2.50
AnalystConsensusTarget US$14.00
Zwfis US$4.23
Fair ValueUS$14.00
Share PriceUS$2.50
82.1% undervalued intrinsic discount
Protalix BioTherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 69 Fair Values set on narratives written by author
PLX Community Narratives
AN
Fair Value US$14 82.1% undervalued intrinsic discount
EMA Reviews And Rare Disease Trends Will Open Global Markets
2users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
ZW
Fair Value US$4.23 40.9% undervalued intrinsic discount
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Protalix BioTherapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.079
- Gross Margin
- 57.53%
- Net Profit Margin
- 10.13%
- Debt/Equity Ratio
- 0%
Protalix BioTherapeutics, Inc. Competitors
Snowflake Analysis
About PLX
- Founded
- n/a
- Employees
- 213
- CEO
- WebsiteView website
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
The market is up 1.1% over the last week, with the Information Technology sector leading the way, up 1.9%. In the last year, the market has climbed 19%. Earnings are forecast to grow by 15% annually. Market details ›